Evidence map›Paper›PMID 41329303›Full record

ReviewHead and neck pathology2025

Ghost Cell Odontogenic Carcinoma: Case Series and Literature Review.

Dalja Parks, Nancy J Zhou, Danny A Vazquez, Matthew Fisher, Sakar Budhathoki, Jergin Chen, Shawn Iganej, Onita Bhattasali, Lester D R Thompson

Abstract readCase ReportsReview
In one paragraph

Review in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dalja ParksDepartment of Clinical Sciences, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA. Dalja.parks@kp.org.
Nancy J ZhouDepartment of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, CA, USA. Nancy.J.Zhou@kp.org.
Danny A VazquezDepartment of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, CA, USA.
Matthew FisherDepartment of Clinical Sciences, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
Sakar BudhathokiDepartment of Clinical Sciences, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
Jergin ChenDepartment of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, CA, USA.
Shawn IganejDepartment of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, CA, USA.
Onita BhattasaliDepartment of Clinical Sciences, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
Lester D R ThompsonHead and Neck Pathology Consultations, Woodland Hills, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ghost cell odontogenic carcinoma (GCOC) is rare. These tumors can arise from odontogenic precursors or de novo, displaying a spectrum of clinical behaviors with potential for rapid local recurrence, distant metastasis, and death from disease. Considering limited data, we present two cases of GCOC in female patients and perform a comprehensive review of the literature related to GCOC with a focus on adjuvant therapies. The first case, a de novo occurrence, had an aggressive course, while the second, arising from an ameloblastoma, was more indolent. A review of 65 previously published cases revealed that 82% of GCOCs occurred in males. Recurrence rates were higher in cases arising from precursor lesions (64%) compared with de novo lesions (26%). Of the 59 patients who had documented follow-up, 37% had an isolated local recurrence, 3% had an isolated distant metastasis, and 5% had both a local recurrence and distant metastasis. Overall, GCOC is a rare but aggressive odontogenic carcinoma requiring a multidisciplinary approach. Radical surgical excision with clear margins remains the primary treatment. Adjuvant therapies, such as radiotherapy, are indicated for aggressive features like rapid growth, positive margins, and local recurrence. While both local and distant recurrences are a risk, local recurrence is the most common mode of treatment failure. Further research into prognostic markers such as CTNNB1, p53, and Ki-67 may lead to more personalized therapies and improved outcomes. Additional research should also focus on intensifying adjuvant therapies to improve outcomes.

Indexed as

Mandibular NeoplasmsOdontogenic TumorsAdultFemaleHumansMiddle AgedCarcinomaGhost cell odontogenic carcinomaJaw neoplasmsMalignant dentinogenic ghost cell tumorOdontogenic cyst, calcifyingOdontogenic tumors

Identifiers

PMID41329303
PMCPMC12672967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.